Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of metoprolol on cytokine levels in chronic heart failure - A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF)
Autore:
Gullestad, L; Ueland, T; Brunsvig, A; Kjekshus, J; Simonsen, S; Froland, SS; Aukrust, P;
Indirizzi:
Rikshosp, Dept Med, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway Rikshosp Oslo Norway N-0027 in Immunol & Infect Dis, N-0027 Oslo, Norway Rikshosp, Internal Med Res Inst, N-0027 Oslo, Norway Rikshosp Oslo Norway N-0027 , Internal Med Res Inst, N-0027 Oslo, Norway Rikshosp, Endocrinol Sect, N-0027 Oslo, Norway Rikshosp Oslo Norway N-0027 kshosp, Endocrinol Sect, N-0027 Oslo, Norway Rikshosp, Dept Cardiol, Div Heart & Lung Dis, N-0027 Oslo, Norway Rikshosp Oslo Norway N-0027 l, Div Heart & Lung Dis, N-0027 Oslo, Norway
Titolo Testata:
AMERICAN HEART JOURNAL
fascicolo: 3, volume: 141, anno: 2001,
pagine: 418 - 421
SICI:
0002-8703(200103)141:3<418:EOMOCL>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
NECROSIS-FACTOR-ALPHA; LEFT-VENTRICULAR DYSFUNCTION; INTERLEUKIN-2 RECEPTOR LEVELS; DILATED CARDIOMYOPATHY; CIRCULATING LEVELS; CARDIAC MYOCYTES; ACTIVATION; DISEASE; MYOCARDITIS; APOPTOSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Aukrust, P Rikshosp, Dept Med, Sect Clin Immunol & Infect Dis, Sognsvannsveien 20, N-0027 Oslo, Norway Rikshosp Sognsvannsveien 20 Oslo Norway N-0027 27 Oslo, Norway
Citazione:
L. Gullestad et al., "Effect of metoprolol on cytokine levels in chronic heart failure - A substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF)", AM HEART J, 141(3), 2001, pp. 418-421

Abstract

Background Enhanced immune activation has been suggested to be involved inthe pathogenesis of congestive heart failure (CHF). There is evidence for interactions between the sympathetic nervous system and the immune system. We therefore examined the effect of the selective beta (1)-receptor blockermetoprolol on various immunologic variables in CHF. Methods Eighty-one patients with CHF were randomized to metoprolol or placebo in a double-blind trial. Plasma levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-10, soluble IL-2 receptor (sIL-2R), monocyte chemoattractant peptide-1, and IL-8 were measured at baseline, after 3 months, and at the end of the study (11.4 +/- 0.4 months). Results our main findings were III at baseline TNF-alpha, IL-6, IL-8, monocyte chemoattractant peptide-l,and sIL-2R but not IL-10 levels were markedly elevated in patients with CHF compared with controls; (2) during treatment with metoprolol, but not with placebo, there was a significant decrease in sIL-2R after 3 months, with a return to baseline at the end of the study;and (3) levels of all other immunologic variables remained unchanged throughout the study in both the metoprolol and the placebo groups. Conclusions our findings suggest that metoprolol treatment in CHF is associated with a significant but temporary decrease in sIL-2R, possibly reflecting down-modulation of T-cell activation. However, an enhanced immune activation also persisted in the metoprolol group, suggesting a potential for more specific immunomodulatory therapy in CHF.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 18:13:09